Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-12-07
2009-08-25
Seaman, D. Margaret (Department: 1625)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07579474
ABSTRACT:
The present invention relates to compounds having therapeutic effects against disorders in the central nervous system, and in particular substituted hydroxypiperidines of the formula 1:wherein R1, R2, and R3 are as defined herein.
REFERENCES:
patent: 3326916 (1967-06-01), Creighton et al.
patent: 3539573 (1970-11-01), Schmutz et al.
patent: 4048314 (1977-09-01), Kubela et al.
patent: 4202898 (1980-05-01), Depoortere
patent: 4333942 (1982-06-01), Eistetter et al.
patent: 4415736 (1983-11-01), Ciganek et al.
patent: 4485109 (1984-11-01), Ciganek
patent: 4504660 (1985-03-01), Klaubert et al.
patent: 5462947 (1995-10-01), Svensson et al.
patent: 5502050 (1996-03-01), Gross
patent: 6175015 (2001-01-01), Yuan et al.
patent: 6924374 (2005-08-01), Sonesson et al.
patent: 2003/0109532 (2003-06-01), Sonesson et al.
patent: 0060179 (1982-02-01), None
patent: 0369887 (1989-11-01), None
patent: 0094159 (1990-04-01), None
patent: 0533267 (1992-09-01), None
patent: 0867183 (2004-10-01), None
patent: 1060160 (1965-07-01), None
patent: 9109594 (1991-07-01), None
patent: 9218475 (1992-10-01), None
patent: 9300313 (1993-01-01), None
patent: 9304684 (1993-03-01), None
patent: 9811068 (1998-03-01), None
patent: WO 0146145 (2001-06-01), None
patent: WO 0146146 (2001-06-01), None
patent: 02059108 (2002-08-01), None
patent: 2005121087 (2005-12-01), None
patent: 2005121088 (2005-12-01), None
patent: 2006039325 (2006-04-01), None
patent: 2006040155 (2006-04-01), None
patent: 2006040156 (2006-04-01), None
patent: 2007042295 (2007-04-01), None
patent: 8905799 (2007-06-01), None
patent: 2007065655 (2007-06-01), None
Radl et al. STN Accession No. 1999:661865 Document No. 132:35590, Abstract of Journal of Heterocyclic Chemistry (1999), 36(4), 1017-1022.
Rosenfeld et al. STN Accession No. 1977:60610, Document No. 86:60610 Abstract of, Journal of Chromatography (1976),129, 387-92.
Author Unknown; Chapter 17 “Mind-Altering Drugs”; Psychopharmacology: Raven Press, New York, NY; pp. 731, 762 and 763.
Roth et al.,; Chapter 21, “Biochemical Pharmacology of Midbrain Dopamine Neurons” Departments of Pharmacology and Psychiatry, Yale University School of Medicine; New Haven, Connecticut; pp. 227 and 237.
Moore et al.,; Chapter 22, “Dopaminergic Neuronal Systems in the Hypothalamus”; Department of Pharmacology and Toxicology, Michigan State University, East Lansing, Michigan; pp. 245 and 254.
Michael Le Moal; Chapter 25, “Mesocorticolimbic Dopaminergic Neurons Functional and Regulatory Roles”; Psychchobiologie des Comportements Adaptatifs, Brodeaux, France; pp. 283 and 292.
Philip Seeman; Chapter 26, “Dopamine Receptors Clinical Correlates”Departments of Pharmacology and Psychiatry, University of Toronto, Toronto, Ontario, Canada; pp. 295-301.
George F. Koob; Chapter 66, “Animal Models of Drug Addiction” Department of Neuropharmacology: La Jolla, California; pp. 759-760.
Sato et al,.: “Oxidation of fulfides to sulfoxcides and sulfones with 30% hydrogen peroxide under organic solvent-and-halogen-free conditiona”; Department of Chemistry and Research Center for Materials Science, Nagoya University, Chikusa Nagoya, Japan: pp. 2469-2476.
Coyle et al., “Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation”, John Hopkins School of Medical Science, vol. 219; gs. 1184-1190.
Author Unknown; “Effect of Chemical Structure on Antipsychotic Activity:; Burger's Medicinal Chemistry”; pp. 872-873.
Feldman et al., Principles of Neuropsychopharmacology; Chapter 17; “Mind Altering Drugs” 1997, pp. 731, 762-763.
Roth et al., “Biochemical Pharmacology of Midbrain Dopamine Neurons” Psychopharmacology: The Fourth Generation of Progress, Raven Press Ltd.; New York; Chapter 21, 1995, pp. 227 & 237.
Moore et al., “Dopamineregic Neuronal Systems in the Hypothalmus”; Department of Pharmacology & Toxicology; Michigan State University; East Lansing, Michigan; he Fourth Generation of Progress, Raven Press Ltd.; New York; Chapter 22, 1995, pp. 245 & 254.
Moal, “Mesocorticolimbic Dopaminergic Neurons” Psychopharmacology: The Fourth Generation of Progress, Raven Press Ltd.; New York; Chapter 25, 1995, pp. 283-292.
Seeman, “Dopamine Receptors” Psychopharmacology: The Fourth Generation of Progress, Raven Press Ltd.; New York; Chapter 26, 1995, pp. 295-301.
Koob, “Animal Models of Drug Addiction” Psychopharmacology: The Fourth Generation of Progress, Raven Press Ltd.; New York; Chapter 66, 1995, pp. 759-760.
Sato et al., “Oxidation of Sulfides to sulfoxides and sulfones with 30% hydrogen peroxide under organic solvent-and-halogen-free conditions” Department of Chemistry and Research Center for Materials Science, Nagoya University, Tetrahedron 57 (2001) pp. 2469-2476.
Coyle et al., “Alzheimer's Disease: A Disorder of Cortical Cholinergic Innervation” John Hopkins School of Medical Science, vol. 219, Mar. 11, 1983, pp. 1184-1190.
Wolff, Manfred E., Burger's Medicinal Chemistry-4th Edition, Part III; John Wiley & Sons 1979, pp. 872-873.
Sonesson Clas
Swanson Lars
Waters Nicholas
Chandrakumar Nizal S
Gauthier & Connors LLP
NSAB, Filial AF Neurosearch AB, Sverige
Seaman D. Margaret
LandOfFree
Substituted piperidines as modulators of dopamine... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted piperidines as modulators of dopamine..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted piperidines as modulators of dopamine... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4140358